• We plan to be the source of yield improvement and stress-tolerance genetics for many crops with or without transgenic or genome edited varieties in the marketplace through licensing of our extensive IP, establishment of Joint Ventures, and Product Co- Development.
  • Revenues will come from upfront technology licensing fees, benchmark payments for proof of concept, commercial development & regulatory submissions, and recurring revenues from trailing royalties on commercialized products; and Collaborations sharing income from sales of yield-enhanced and stress-tolerant seeds.

Use of Proceeds (Seed Round Benchmarks):

  • Maintain IP and file new applications
  • Initiate Genetically Modified or Genome Edited alfalfa
  • Form collaborations or license technology in 3 other crops
  • Working Capital

Funding Goal:

Seeking Seed Round funding up to $950,000 in Convertible Notes from SEC-accredited investors under very favorable terms.  $350,000 has already been raised.

Investors

Competitive Advantages:
  • Only field-demonstrated, broadly applicable transgenic technology to significantly improve crop yields
  • Domain technical & licensing expertise
  • Dominant IP in plant yield genes:  16 issued US Patents, several applications, and counterparts in many countries
  • Secondary benefits in stress tolerance, disease resistance & improved shelf life
  • Extremely low operating costs